Thank you to PharmaVoice for the opportunity to discuss Anokion and our immune tolerance approach to diseases, including our clinical trials for #multiplesclerosis and #celiacdisease. https://lnkd.in/efQxCzM3
Anokion
Biotechnology Research
Cambridge, Massachusetts 4,093 followers
Restoring normal IMMUNE TOLERANCE to treat autoimmune disease
About us
Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease.
- Website
-
http://www.anokion.com
External link for Anokion
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Specialties
- Immunoengineering, Protein engineering, Biologics, and Autoimmune diseases
Locations
-
Primary
Get directions
50 Hampshire St
Cambridge, Massachusetts 02139, US
-
Get directions
EPFL Innovation Park - L
Ecublens, CH
Employees at Anokion
Updates
-
The Anokion team will be participating in the BofA Healthcare Trailblazers Conference on October 26, 2023, in Boston. We look forward to discussing our clinical-stage immune tolerance programs for #celiacdisease and #multiplesclerosis. https://lnkd.in/edTkVCvH
-
-
The Anokion team is looking forward to attending the UEG - United European Gastroenterology Week and discussing the Phase 1 clinical data with celiac disease treatment candidate KAN-101 during an oral presentation on Monday, October 16 at 4 p.m. CEST. We look forward to discussing the results from the completed trial, which supported initiation of our Phase 2 global program. #UEGWeek https://lnkd.in/esmijzHx
-